Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 8/20 | 0.34 |
| ▸ | RAB9A | P51151 | 8/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.34 |
| ▸ | TP53 | P04637 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.34 |
| ▸ | RELA | Q04206 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.34 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.33 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.33 |
| ▸ | ZAP70 | P43403 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15228441 | 1.00 | CYP19A1 (0.36) | CYP19A1NPC1RAB9AALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL15228344 | 0.99 | CYP19A1 (0.35) | CYP19A1NPC1RAB9AALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL15228454 | 0.99 | CYP19A1 (0.35) | CYP19A1NPC1RAB9AALDH1A1SMN1; SMN2 | |
| Hypochlorous Acid SCHEMBL21486083 | 0.97 | CYP19A1 (0.36) | CYP19A1NPC1RAB9AALDH1A1SMN1; SMN2 | |
| Hypochlorous Acid SCHEMBL21486023 | 0.97 | CYP19A1 (0.36) | CYP19A1NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL21515516 | 0.88 | CYP19A1 (0.36) | CYP19A1NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL16782218 | 0.87 | CYP19A1 (0.39) | CYP19A1NPC1RAB9AALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL15228343 | 0.86 | CYP19A1 (0.39) | CYP19A1NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL15065965 | 0.85 | MAPT (0.37) | CYP19A1NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL15065783 | 0.85 | MAPT (0.37) | CYP19A1NPC1RAB9AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2819519-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2019-10-23 | — | — | EP | claimed |
| US-9371336-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | claimed |
| US-20150166575-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC. (US) | 2015-06-18 | — | — | US | claimed |
| EP-2819519-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2019-10-23 | — | — | EP | disclosed |
| US-9371336-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371336-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150166575-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150166575-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC. (US) | 2015-06-18 | — | — | US | disclosed |
| EP-2819519-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013130689-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166575-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | CYP19A1 3171/4885NPC1 975/4885RAB9A 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.